Liver Metastases SBRT: Ready for Prime Time? - Dr. Daniel Chang

Liver Metastases SBRT: Ready for Prime Time?
Dr. Daniel Chang MD
The Princess Margaret Cancer Centre, Toronto, Canada
Liver SBRT has been increasingly used for liver tumors, specifically liver metastases and primary liver cancers. The data up to this point show a high degree of local control on par with other liver-directed therapies. The focus of future research on liver SBRT should focus on areas beyond outcome, such as normal tissue tolerance, quality of life, histology-specific outcomes, and risk stratification to best determine who most benefits from treatment. This session will review the current literature and putting them into context with other liver directed therapies and discuss how liver SBRT can continue to expand its indications for use.
Live webinar from the AEP Liver SBRT IGRT Education Course offering, March 5-7, 2015
For more information on the Accelerated Education Program, visit us at www.aepeducation.ca
Follow us at / aepcme